logo Click here for the Chao Family Comprehensive Cancer Center Home Page Click here for the UC Irvine Home Page

Cancer Control

Program Leader

Karen Edwards, Ph.D.

Sunmin Lee, ScD


Program Overview

The goal of the Cancer Control (CC) program is to foster and facilitate research designed to identify and reduce cancer risk, and to improve cancer outcomes throughout the disease continuum. CC members represent a broad range of disciplines, including genetics, epidemiology, social and behavioral science, clinical oncology, biostatistics, health economics/services, and public health.

CC research studies are focused on three areas:

1. To develop and test strategies to reduce cancer susceptibility in high risk populations »

Chemoprevention scientists have continued their rigorous tests of hypothesis-driven investigator initiated trials which included intra- and inter-programmatic collaborations between clinical investigators, basic scientists, and quantitative researchers. This well-developed area of research continues to benefit from programmatic collaborations which have yielded national studies with translational endpoints. More recently, social and behavioral scientists have received support to examine factors associated with adolescent nicotine uptake, including marketing, social networks, and biomarker correlations to ADHD.

2. To identify factors that assess disease and treatment outcomes »

Inter-programmatic collaborations have, for example, led to discovery of a genetic panel which can predict treatment outcome for prostate cancer patients, and patient-reported data can predict mortality, poor function and hospitalizations in these patients. CC will continue to foster new collaborations to innovative approaches to evaluation of treatment type, costs, and decision-making as it affects cancer patients.

3. To test innovative interventions to improve cancer control and quality of life for cancer survivors »

The CC interdisciplinary collaborative teams of clinical, behavioral and basic scientists have formed inter- and intra-programmatic collaborations to provide interventions for vulnerable cancer survivor populations. CC is working with new cancer center leadership to identify promising translational approaches which have relevance to our catchment area, and beyond.

In addition, CC continues to benefit from the robust chemoprevention and genetic epidemiology science legacies, while also experiencing an infusion of transdisciplinary collaborations created to improve cancer outcomes and survivorship. Taken together, CC improves the current knowledgebase and enhances cancer care within our community.


Ahlering, Thomas
Anton-Culver, Hoda
Benmohamed, Lbachir
Bota, Daniela
Bristow, Robert
Chang, Kenneth
De Alba, Israel
Edwards, Karen
Evans, Gregory
Fortier, Michelle
Gehricke, Jean
Gillen, Daniel
Grando, Sergei
Greenfield, Sheldon
Hopfer, Suellen
Hoyt, Michael
Jafari, Mehraneh
Kleinman, Michael
Kong, Xiao-Tang
Kuan, Edward
Lakon, Cynthia
Lane, Karen
Lee, Sunmin
Liu, Feng
Lu, Yunxia
Luderer, Ulrike
Luo, Zhigang
McClelland, Michael
McLaren, Christine
McLaren, Gordon
Mercola, Dan
Meyskens, Frank
Morgan, Timothy
Park, Hannah
Pechman, Cornelia
Stamos, Michael
Tanjasiri, Sora
Tewari, Krishnansu
Timberlake, David
Uchio, Edward
Vieira, Veronica
Wenzel, Lari
Zell, Jason
Zi, Xiaolin
Ziogas, Argyrios